News from harbour biomed A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 10, 2022, 04:54 ET Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting

Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of...

May 05, 2022, 20:00 ET Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

Harbour BioMed ("HBM", HKEX:02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel...

Apr 13, 2022, 20:46 ET Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical Officer

Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), today announced the appointment of Dr. Humphrey Gardner as Chief Medical Officer (CMO). Dr....

Apr 06, 2022, 21:09 ET Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022

Harbour BioMed ("HBM", "the Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization ...

Apr 06, 2022, 03:04 ET Harbour BioMed Announces Poster Presentation on the Novel Bispecific Antibody PD-L1xCD40 at Upcoming American Association for Cancer Research (AACR) Annual Meeting

Harbour BioMed ("HBM", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel...

Mar 24, 2022, 22:22 ET Harbour BioMed Reports Full Year 2021 Financial Results: Empower Value Creation with Global Innovation Capabilities

Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and...

Feb 27, 2022, 23:06 ET Harbour BioMed Announces Approval for Phase I Trial of B7H4x4-1BB Bispecific Antibody in Australia

Harbour BioMed ("HBM", HKEX: 02142) announced that, it has been approved by the Institutional Review Boards (the "IRBs") to commence phase I trial of ...

Feb 21, 2022, 07:29 ET Harbour BioMed Announces IND Approval for Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

Harbour BioMed ("HBM", HKEX: 02142) announced that China National Medical Products Administration (NMPA) had approved its investigational new drug...

Jan 24, 2022, 02:39 ET Harbour BioMed Announces Dosing of First Patient in Combination Therapy Phase Ib/IIa Trial of Next-Generation Anti-CTLA-4 Antibody

Harbour BioMed ("HBM", HKEX: 02142) announced that, it has successfully completed the dosing of first patient in phase Ib/IIa trial at the stage of...

Jan 04, 2022, 04:28 ET Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003

Harbour BioMed ("HBM", HKEX: 02142) announced that, its next generation anti-CTLA-4 fully human heavy-chain only antibody (HCAb), HBM4003, has...

Dec 02, 2021, 04:58 ET Harbour BioMed Appoints Mr. Weihao Xu as Chief Strategy Officer

Harbour BioMed ("HBM", HKEX:02142) is pleased to announce the appointment of Mr. Weihao Xu as Chief Strategy Officer (CSO), who will base in San...

Oct 19, 2021, 05:52 ET Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase II Trial in Patients with Thyroid Eye Disease

Harbour BioMed ("HBM", HKEX: 02142) announced that, the clinical trial of its anti-FcRn antibody, batoclimab (HBM9161), has completed the first...

Sep 27, 2021, 09:03 ET Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase III Trial in Patients with Generalized Myasthenia Gravis

Harbour BioMed ("HBM", HKEX: 02142) announced that, the clinical trial of its anti-FcRn antibody, batoclimab (HBM9161), has completed the first...

Sep 14, 2021, 01:10 ET Harbour BioMed Announces NMPA Approval of Two IND Applications for Next-Generation Anti-CTLA-4 Antibody HBM4003

Harbour BioMed ("HBM", HKEX: 02142) announced that the China National Medical Products Administration (NMPA) has approved its Investigational New...

Sep 13, 2021, 02:34 ET Harbour BioMed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003

Harbour BioMed ("HBM", HKEX: 02142) announced positive results from its phase I dose escalation clinical trial of HBM4003 in solid tumors in...

Sep 01, 2021, 01:05 ET Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China

Harbour BioMed ("HBM", HKEX: 02142) today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration...

Aug 31, 2021, 01:47 ET Harbour BioMed Reports 2021 Interim Results

Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and...

Jul 26, 2021, 07:11 ET HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021

Harbour BioMed ("HBM", HKEX: 02142) today announced that the abstract detailing clinical data from its Australian phase I study of next-generation...

Jul 20, 2021, 09:53 ET Harbour BioMed Appoints Yingying Chen, PhD, as Chief Financial Officer

Harbour BioMed ("HBM", HKEX:02142) announced the appointment of Dr. Yingying Chen as Chief Financial Officer (CFO). Dr. Chen will be responsible for...

Jul 06, 2021, 09:06 ET Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis

Harbour BioMed ("HBM", HKEX: 02142) today announced positive topline results from its Phase 2 proof-of-concept clinical trial of batoclimab (HBM9161) ...

Jun 17, 2021, 03:41 ET Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC

Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer...

Jun 16, 2021, 01:08 ET Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment

Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cancer...

May 11, 2021, 06:03 ET Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody

Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient in its part 2 of phase I (phase Ib/IIa) clinical study of its...

Apr 13, 2021, 02:55 ET Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting

Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company, presents its newly discovered fully human anti-B7H7...

Mar 21, 2021, 20:30 ET Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China

Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients ...